Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by J. Stern & Co. LLP

J. Stern & Co. LLP increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,538 shares of the medical research company's stock after purchasing an additional 3,198 shares during the quarter. Thermo Fisher Scientific makes up 2.8% of J. Stern & Co. LLP's holdings, making the stock its 19th largest position. J. Stern & Co. LLP's holdings in Thermo Fisher Scientific were worth $29,933,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. FPC Investment Advisory Inc. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. Missouri Trust & Investment Co purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $29,000. Pillar Financial Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $29,000. Finally, Endeavor Private Wealth Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $30,000. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the transaction, the chief financial officer now owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 over the last quarter. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO traded down $2.69 on Monday, reaching $421.55. 2,527,205 shares of the company's stock were exchanged, compared to its average volume of 1,746,667. The stock has a market cap of $159.13 billion, a PE ratio of 25.50, a P/E/G ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a twelve month low of $409.85 and a twelve month high of $627.88. The stock's fifty day moving average price is $487.28 and its 200-day moving average price is $526.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter last year, the firm earned $5.11 earnings per share. The business's revenue for the quarter was up .2% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.41%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Analysts Set New Price Targets

TMO has been the subject of a number of research reports. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday. StockNews.com lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Friday. Citigroup decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. UBS Group reduced their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday. Finally, Scotiabank dropped their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $616.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.